Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis
Takehiko Dohi, … , Janet Plescia, Dario C. Altieri
Takehiko Dohi, … , Janet Plescia, Dario C. Altieri
Published October 15, 2004
Citation Information: J Clin Invest. 2004;114(8):1117-1127. https://doi.org/10.1172/JCI22222.
View: Text | PDF
Article Oncology Article has an altmetric score of 4

Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis

  • Text
  • PDF
Abstract

Evasion of apoptosis is a hallmark of cancer, but the molecular circuitries of this process are not understood. Here we show that survivin, a member of the inhibitor of apoptosis gene family that is overexpressed in cancer, exists in a novel mitochondrial pool in tumor cells. In response to cell death stimulation, mitochondrial survivin is rapidly discharged in the cytosol, where it prevents caspase activation and inhibits apoptosis. Selective targeting of survivin to mitochondria enhances colony formation in soft agar, accelerates tumor growth in immunocompromised animals, and abolishes tumor cell apoptosis in vivo. Therefore, mitochondrial survivin orchestrates a novel pathway of apoptosis inhibition, which contributes to tumor progression.

Authors

Takehiko Dohi, Elena Beltrami, Nathan R. Wall, Janet Plescia, Dario C. Altieri

×

Figure 6

Options: View larger image (or click on image) Download as PowerPoint
Adenoviral targeting of survivin to mitochondria inhibits apoptosis. (A)...
Adenoviral targeting of survivin to mitochondria inhibits apoptosis. (A) Subcellular localization. INS-1 cells were infected with pAd-MTS, and isolated mitochondrial or cytosolic fractions were analyzed by immunoblotting. The position of endogenous or transduced (HA-MTS) survivin is indicated. (B) Cytoprotection by adenoviral transduction. INS-1 cells transduced with pAd-MTGFP or pAd-MTS were treated with UVB, exposed to serum starvation, or treated with staurosporine, and analyzed for DNA content by flow cytometry. Samples labeled as INS-1 were untreated cultures. The percentage of cells with hypodiploid (apoptotic) DNA content is indicated for each condition tested. (C) Mitochondrial survivin is sufficient for cytoprotection. MCF-7 cells were transduced with pAd-MTGFP, pAd-Survivin, or pAd-MTS, treated with staurosporine, and analyzed for hypodiploid DNA content and immunoblotting of whole cell extracts (W), mitochondrial, or cytosolic fractions. The percentages of cells with hypodiploid (apoptotic) DNA content were 47% (nontransduced cultures, data not shown), 40% (pAd-MTGFP), 25% (pAd-Survivin), and 29% (pAd-MTS).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 5 patents
Mentioned by 1 peer review sites
10 readers on Mendeley
See more details